EBRO 2017

Summary

• 3 HGG; 2 LGG; 3 Mets • No meningioma, pituitary, medulloblastoma, pilocytic astrocytoma • Focus on treatment and prognosis • For glioma, grade still matters • But molecular pathology is becoming more important for risk stratification • We are not going to reduce the dose in IDH-mut GBM

• Brain mets – still poor evidence base

• Clinically fascinating area • Good mix of technology and humanity